Latest News
FDA Approves Johnson & Johnson's RYBREVANT FASPRO amivantamab and hyaluronidase-lpuj for a First-Line Combination Regimen when Combined with LAZCLUZE lazertinib
Details >FDA approves Daiichi Sankyo's fam-trastuzumab deruxtecan-nxki with pertuzumab for unresectable or metastatic HER2-positive breast cancer
Details >FDA Approves Johnson & Johnson's Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-sensitive Prostate Cancer
Details >Oral Chemotherapy Copay and Coinsurance Cap Coming Jan. 1, 2026
Blue Cross Blue Shield of Michigan Announcement
Details >Report Broken Links
Have you encountered a problem with a URL (link) on this page not working or displaying an error message? Help us fix it!
